102 related articles for article (PubMed ID: 16236516)
1. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy.
Osborne CK; Schiff R; Arpino G; Lee AS; Hilsenbeck VG
Breast; 2005 Dec; 14(6):458-65. PubMed ID: 16236516
[TBL] [Abstract][Full Text] [Related]
2. Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy.
Díaz Flaqué MC; Galigniana NM; Béguelin W; Vicario R; Proietti CJ; Russo R; Rivas MA; Tkach M; Guzmán P; Roa JC; Maronna E; Pineda V; Muñoz S; Mercogliano M; Charreau EH; Yankilevich P; Schillaci R; Elizalde PV
Breast Cancer Res; 2013 Dec; 15(6):R118. PubMed ID: 24345432
[TBL] [Abstract][Full Text] [Related]
3. Tracking progesterone receptor-mediated actions in breast cancer.
Knutson TP; Lange CA
Pharmacol Ther; 2014 Apr; 142(1):114-25. PubMed ID: 24291072
[TBL] [Abstract][Full Text] [Related]
4. Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling.
Singhal H; Greene ME; Zarnke AL; Laine M; Al Abosy R; Chang YF; Dembo AG; Schoenfelt K; Vadhi R; Qiu X; Rao P; Santhamma B; Nair HB; Nickisch KJ; Long HW; Becker L; Brown M; Greene GL
Oncotarget; 2018 Jan; 9(4):4282-4300. PubMed ID: 29435103
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer.
Abdel-Hafiz HA
Diseases; 2017 Jul; 5(3):. PubMed ID: 28933369
[TBL] [Abstract][Full Text] [Related]
6. From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells.
Barazetti JF; Jucoski TS; Carvalho TM; Veiga RN; Kohler AF; Baig J; Al Bizri H; Gradia DF; Mader S; Carvalho de Oliveira J
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359587
[TBL] [Abstract][Full Text] [Related]
7. Anti-MUC1 nanobody can synergize the Tamoxifen and Herceptin effects on breast cancer cells by inducing ER, PR and HER2 overexpression.
Shokrollahi Barough M; Jalili N; Shafiee S; Salehi M; Naseri N; Javidi MA; Hosseinzadeh A; Farahmand L
Int Immunopharmacol; 2023 Nov; 124(Pt A):110792. PubMed ID: 37633239
[TBL] [Abstract][Full Text] [Related]
8. Molecular Imaging of Steroid Receptors in Breast Cancer.
Keigley QJ; Fowler AM; O'Brien SR; Dehdashti F
Cancer J; 2024 May-Jun 01; 30(3):142-152. PubMed ID: 38753748
[TBL] [Abstract][Full Text] [Related]
9. Targeting nuclear hormone receptors for the prevention of breast cancer.
Moyer CL; Brown PH
Front Med (Lausanne); 2023; 10():1200947. PubMed ID: 37583424
[TBL] [Abstract][Full Text] [Related]
10. The Role of Progesterone Receptors in Breast Cancer.
Li Z; Wei H; Li S; Wu P; Mao X
Drug Des Devel Ther; 2022; 16():305-314. PubMed ID: 35115765
[TBL] [Abstract][Full Text] [Related]
11. HER2-positive pure mucinous breast carcinoma: A case report and literature review.
Zhao X; Yang X; Gao R; Zhai L; Yang L; Yu K
Medicine (Baltimore); 2020 Aug; 99(33):e20996. PubMed ID: 32871976
[TBL] [Abstract][Full Text] [Related]
12. Estrogen Receptor Positive and Progesterone Receptor Negative Breast Cancer: the Role of Hormone Therapy.
Dembinski R; Prasath V; Bohnak C; Siotos C; Sebai ME; Psoter K; Gani F; Canner J; Camp MS; Azizi A; Jacobs L; Habibi M
Horm Cancer; 2020 Aug; 11(3-4):148-154. PubMed ID: 32519274
[TBL] [Abstract][Full Text] [Related]
13. Naturally-Occurring Canine Mammary Tumors as a Translational Model for Human Breast Cancer.
Gray M; Meehan J; Martínez-Pérez C; Kay C; Turnbull AK; Morrison LR; Pang LY; Argyle D
Front Oncol; 2020; 10():617. PubMed ID: 32411603
[TBL] [Abstract][Full Text] [Related]
14. Suboptimal concordance in testing and retesting results of triple-negative breast carcinoma cases among laboratories: one institution experience.
De Jesus J; Rosa M
Cancer Cell Int; 2019; 19():263. PubMed ID: 31632197
[TBL] [Abstract][Full Text] [Related]
15. The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer.
Rodriguez D; Ramkairsingh M; Lin X; Kapoor A; Major P; Tang D
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31336602
[TBL] [Abstract][Full Text] [Related]
16. Current biomarkers of canine mammary tumors.
Kaszak I; Ruszczak A; Kanafa S; Kacprzak K; Król M; Jurka P
Acta Vet Scand; 2018 Oct; 60(1):66. PubMed ID: 30373614
[TBL] [Abstract][Full Text] [Related]
17. The Role of Steroid Hormones in Breast and Effects on Cancer Stem Cells.
Alferez DG; Simões BM; Howell SJ; Clarke RB
Curr Stem Cell Rep; 2018; 4(1):81-94. PubMed ID: 29600163
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Biological Evaluations of Ring Substituted Tetrahydroisoquinolines (THIQs) as Anti-Breast Cancer Agents.
Eyunni SV; Gangapuram M; Mochona B; Mateeva N; Redda KK
J Cancer Sci Ther; 2017; 9(7):528-540. PubMed ID: 29430288
[TBL] [Abstract][Full Text] [Related]
19. Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools.
Martínez-Montiel N; Anaya-Ruiz M; Pérez-Santos M; Martínez-Contreras RD
Genes (Basel); 2017 Oct; 8(10):. PubMed ID: 28981467
[TBL] [Abstract][Full Text] [Related]
20. Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells.
Fettig LM; McGinn O; Finlay-Schultz J; LaBarbera DV; Nordeen SK; Sartorius CA
Oncogene; 2017 Nov; 36(44):6074-6084. PubMed ID: 28692043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
